206 related articles for article (PubMed ID: 15797254)
1. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
Frost GI; Lustgarten J; Dudouet B; Nyberg L; Hartley-Asp B; Borgström P
Microvasc Res; 2005 Jan; 69(1-2):1-9. PubMed ID: 15797254
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
3. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
5. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
6. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
7. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
9. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade.
Li H; Gerald WL; Benezra R
Cancer Res; 2004 Sep; 64(17):6137-43. PubMed ID: 15342397
[TBL] [Abstract][Full Text] [Related]
10. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.
Tang Y; Wang L; Goloubeva O; Khan MA; Zhang B; Hussain A
Clin Cancer Res; 2008 May; 14(10):2936-43. PubMed ID: 18483360
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model.
Källberg E; Wikström P; Bergh A; Ivars F; Leanderson T
Prostate; 2010 Sep; 70(13):1461-70. PubMed ID: 20687219
[TBL] [Abstract][Full Text] [Related]
15. The roles of epithelial-mesenchymal interactions and the innate immune response on the tumorigenicity of human prostate carcinoma cell lines grown in immuno-compromised mice.
Frost GI; Dudouet B; Lustgarten J; Borgström P
In Vivo; 2003; 17(5):377-88. PubMed ID: 14598599
[TBL] [Abstract][Full Text] [Related]
16. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
17. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
[TBL] [Abstract][Full Text] [Related]
18. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management.
Ghosh R; Graham H; Rivas P; Tan XJ; Crosby K; Bhaskaran S; Schoolfield J; Banu J; Fernandes G; Yeh IT; Kumar AP
Anticancer Res; 2010 Mar; 30(3):857-65. PubMed ID: 20393007
[TBL] [Abstract][Full Text] [Related]
19. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
20. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
Wong SY; Haack H; Crowley D; Barry M; Bronson RT; Hynes RO
Cancer Res; 2005 Nov; 65(21):9789-98. PubMed ID: 16267000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
